Red Light Therapy for Chronic Pain

Understanding Chronic Pain

Chronic pain — defined as pain lasting longer than three months — affects an estimated 20% of adults worldwide. Unlike acute pain, which serves as a protective warning signal, chronic pain often persists beyond the expected healing period and may involve changes in the nervous system that maintain pain even after the original injury has resolved. This phenomenon, known as central sensitisation, involves amplified pain processing in the spinal cord and brain.

Chronic pain conditions include low back pain, osteoarthritis, fibromyalgia, neuropathic pain, complex regional pain syndrome, migraines, and many others. The impact extends far beyond physical suffering — chronic pain affects mental health, sleep, relationships, work capacity, and overall quality of life. Current management strategies include medications (from paracetamol to opioids), physical therapy, psychological approaches, interventional procedures, and increasingly, non-pharmacological complementary therapies.

How Red Light Therapy May Help

Photobiomodulation (PBM) may address chronic pain through multiple converging mechanisms:

• Peripheral nerve modulation: Near-infrared wavelengths (810–1060 nm) may reduce the excitability of peripheral nociceptors (pain receptors), potentially interrupting the pain signal at its source.
• Anti-inflammatory cascade: PBM may down-regulate NF-kB signalling, reduce pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6), and decrease prostaglandin production — addressing the biochemical foundations of many chronic pain states.
• Endorphin release: Some research suggests PBM may stimulate the release of endogenous opioids (beta-endorphins), providing natural analgesic effects.
• Mitochondrial restoration: Emerging research links mitochondrial dysfunction to chronic pain conditions. By enhancing ATP production, PBM may help restore normal cellular function in pain-affected tissues.
• Central sensitisation modulation: While most PBM research focuses on peripheral mechanisms, there is emerging evidence that systemic PBM may influence central pain processing, potentially through improved brain mitochondrial function and reduced neuroinflammation.

What the Research Says

A 2015 comprehensive review by Chow and colleagues in The Lancet noted that LLLT "can offer clinically meaningful pain relief" for chronic joint disorders and musculoskeletal pain when appropriate dosing parameters are used. A 2010 meta-analysis in PLOS ONE pooled data from 16 RCTs on LLLT for chronic neck pain and found that LLLT was significantly more effective than placebo for both short-term and intermediate-term pain relief.

A 2018 systematic review in BMJ Open examined PBM for chronic non-specific low back pain and found moderate evidence supporting pain reduction and functional improvement. A separate 2020 RCT in Pain Research and Management demonstrated that PBM reduced Visual Analog Scale (VAS) pain scores by 40% in patients with chronic musculoskeletal pain, with improvements maintained at 3-month follow-up.

Perhaps most compelling for chronic pain patients, a 2019 review in Journal of Pain Research highlighted the potential for PBM to reduce opioid consumption in chronic pain populations, a finding with significant public health implications.

Dosing Matters

Research consistently emphasises that PBM follows a biphasic dose response — too little energy may be ineffective, while too much can be inhibitory. For chronic pain, the therapeutic window appears to be 4–12 J/cm² at the target tissue, delivered with clinical-grade irradiance to ensure adequate penetration.

Recommended Usage Protocol

• Full-body sessions: 15–20 minutes, treating affected regions and surrounding areas.
• Distance: 15–30 cm from the treatment area.
• Frequency: 5 sessions per week during an initial 4-week loading phase; 3 sessions per week for maintenance.
• Targeted approach: Focus on primary pain areas, but consider full-body sessions for widespread pain.
• Patience: Chronic pain developed over time — improvement is often gradual, with meaningful changes at 4–8 weeks.

Which Hale Panel Is Best for Chronic Pain?

Chronic pain often involves multiple body regions and benefits from comprehensive coverage. The RLPRO 1200 (864 LEDs, 184 × 42 cm) is the recommended choice for home users, providing full-body coverage in a single standing session. For clinical pain management practices or rehabilitation centres, the RLPRO 2000 (1,152 LEDs, 189 × 58 cm) delivers maximum coverage and power, enabling efficient treatment of diverse pain presentations.

Both models deliver irradiance exceeding 197 mW/cm² — ensuring therapeutic energy reaches deep tissues within practical session times — and are Health Canada Class II and FDA-registered medical devices.

A Comprehensive Pain Management Strategy

• Multidisciplinary pain management (physician, physiotherapist, psychologist)
• Graded exercise and movement therapy — inactivity often worsens chronic pain
• Pain neuroscience education — understanding pain reduces fear and catastrophising
• Mindfulness-based stress reduction (MBSR) and acceptance-based approaches
• Sleep optimisation — poor sleep amplifies pain perception
• Anti-inflammatory nutrition and healthy weight management
• Gradual, supervised reduction of medications where appropriate

Red light therapy may provide chronic pain patients with a safe, non-addictive, side-effect-free modality that complements existing medical care — addressing pain at the cellular and tissue level while supporting the body's innate capacity for healing and adaptation.